dvm36013d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
FierceBiotech29d
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
pharmaphorum5d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
FierceBiotech12d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Business Wire1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...
WebMD6mon
What It Means to Be Patient-Centric
She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...
WATTAgNet14d
Boehringer Ingelheim expands research and development facility
With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...
FiercePharma13d
Boehringer, Amgen, Novartis sweep corporate reputation rankings among cardiovascular patient groups
A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...
Nature4y
Boehringer Ingelheim: Reshaping the course of chronic obstructive pulmonary disease
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...
Financial Post29d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...